BioPharma Drug Discovery
JW Pharmaceutical’s Epaminurad Shows Statistical Superiority in Phase III Gout Trial
-JW Pharmaceutical (KRX:001060) announced that the multinational Phase 3 clinical trial of its gout treatment candidate ‘Epaminurad (code name U...
August 17, 2026 | News
Kyowa Kirin Taps Cognizant and Benchling to Build AI-Powered Drug Discovery Foundation in Japan
Cognizant announced that it will support the introduction and implementation of Benchling, the AI platform for R&D at Tokyo Research Park and Fuji Rese...
August 17, 2026 | News
Insilico Nominates AI-Designed ISM0900 as Preclinical Candidate for Cardiovascular Risk
Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced the nom...
August 14, 2026 | News
China Approves Geneseeq’s PanTRKare as Companion Diagnostic for VELMARTO
NMPA granted approval to Geneseeq's PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectini...
August 14, 2026 | News
Aureka Biotechnologies Raises $100M Series B to Advance AI-Driven Drug Discovery
Aureka Biotechnologies announced the close of a US$100 million Series B financing on Aug. 10, 2026. Granite Asia funded the first tranche exclusively, and ...
August 12, 2026 | News
Innovent, Daiichi Sankyo Partner to Commercialise Vanflyta for FLT3-ITD Positive AML in China
Collaboration to accelerate access to Vanflyta® for patients with newly diagnosed FLT3-ITD positive AML Innovent Bio...
August 11, 2026 | News
Ono and Mediar Partner to Develop Novel Antibody Therapies for Fibro-Inflammatory Diseases
Commencing a drug discovery partnership to create novel antibody therapeutics for fibro-inflammatory diseases with high unmet medical need Leveraging ...
August 10, 2026 | News
Alteogen Signs Up to $365 Million Hybrozyme Licensing Deal for Subcutaneous Biologic
Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme™-based hyaluronidase ALT-B4 Alteogen...
August 07, 2026 | News
Adneuris Licenses Cebranopadol Rights to Maruishi for Japan and South Korea
Agreement Grants Maruishi Rights for the Development and Commercialization of Cebranopadol for Pain in Japan and South Korea, Marking Adneuris' Second Ex...
August 07, 2026 | News
Biocon Launches Interchangeable YESAFILI Biosimilar to EYLEA in the U.S.
Yesafili™ (aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg Potential ...
August 06, 2026 | News
Forlong Biotechnology Completes Pivotal FL115 Manufacturing Milestone Ahead of Phase III NMIBC Trial
Forlong Biotechnology, a clinical-stage biotech company focused on developing transformative cytokine therapies for patients with severe unmet needs, today...
August 06, 2026 | News
Pathos AI Secures Up to $2.2 Billion Global Licensing Deal for Alphamab's First-in-Class Bispecific ADC
Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a licensing agreement with Jiangsu Al...
August 06, 2026 | News
Ascletis Initiates Global Phase III Trial for Oral GLP-1 Obesity Drug ASC30
-Initiated global Phase III program for oral small molecule GLP-1, ASC30, which will enroll approximately 4,600 participants with obesity or overweight acr...
August 05, 2026 | News
From Market Access to Long-Term Growth: Rethinking Biopharma Expansion in APAC
BioPharma APAC speaks with Girisan Kariangal, Regional Vice President – Business Development & Alliance Management, Menarini Asia-Pacific, on the...
August 04, 2026 | Interaction
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
